Skip to main content

Table 1 The results of ophthalmologic examinations in the right eye during the follow-up period

From: Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings

Time points

Eye symptoms

Visual field

ERG

VEP

OCT

Ophthalmoscope examination

Fundus fluorescein angiography

Visual acuity

December 6th, 2017 (during chemotherapy)

Progressive visual loss

Optic disc edema, fuzzy boundary and linear hemorrhages.

0.4

December 29th, 2017 (during chemotherapy)

Progressive visual loss

Optic disc edema, fuzzy boundary and linear hemorrhages.

0.3

January 5th, 2018 (1 week after chemotherapy)

Progressive visual loss

Severe visual field defects

Thinner ILM-RPE at superior side and nasal side

The upper part of the optic disc becoming gray, optic disc edema subsiding and residual retinal hemorrhage on the inferior rim; creases, depigmented macules and hard exudate in the macular area.

Capillary underdevelopment at the nasal and superior temporal area of optic disc in the early phase and capillary fluorescein leakage in the late phase

0.3

January 25th, 2018 (1 month after chemotherapy)

Improved vision

Obviously improved visual field.

Normal amplitudes of a-type wave, b-type wave and P1-type wave.

Lengthened incubation period of P100-type wave in P-VEP test.

Secondary macular epiretinal membrane

Gray optic disc without edema and with clear boundary.

0.4

March 28th, 2018 (3 months after chemotherapy)

Improved vision

Normal incubation period of P2-type wave.

Secondary macular epiretinal membrane.

The optic disc becoming not so gray as before.

0.5

August 13th, 2018 (7.5 months after chemotherapy)

Improved vision

Dramatically improved visual field.

0.5

  1. Note: On October 31st, 2017 the patient received the first cycle of chemotherapy. On November 30th, 2017, she received the second cycle of chemotherapy. On December 29th, 2017, she received the third cycle of chemotherapy. From January 26th, 2018 to March 22th, 2018, she received radiotherapy combined with targeted therapy. VEP visual evoked potential, ERG electroretinogram, OCT optical coherence tomography